People aged 15 to 59 years seen at HIV services in the UK, expressed as a rate per 1,000 population.Data is presented by area of residence, and exclude people diagnosed with HIV in England who are resident in Wales, Scotland, Northern Ireland or abroad.RationaleThe geographical distribution of people seen for HIV care and treatment is not uniform across or within regions in England. Knowledge of local diagnosed HIV prevalence and identification of local risk groups can be used to help direct resources for HIV prevention and treatment.In 2008, http://www.bhiva.org/HIV-testing-guidelines.aspx recommended that Local Authority and NHS bodies consider implementing routine HIV testing for all general medical admissions as well as new registrants in primary care where the diagnosed HIV prevalence exceeds 2 in 1,000 population aged 15 to 59 years.In 2017, guidelines were updated by https://www.nice.org.uk/guidance/NG60 which is co-badged with Public Health England. This guidance continues to define high HIV prevalence local authorities as those with a diagnosed HIV prevalence of between 2 and 5 per 1,000 and extremely high prevalence local authorities as those with a diagnosed HIV prevalence of 5 or more per 1,000 people aged 15 to 59 years.When this is applied to national late HIV diagnosis data, it shows that two-thirds of late HIV diagnoses occur in high-prevalence and extremely-high-prevalence local authorities. This means that if this recommendation is successfully applied in high and extremely-high-prevalence areas, it could potentially affect two-thirds of late diagnoses nationally.Local authorities should find out their diagnosed prevalence published in UKHSA's http://fingertips.phe.org.uk/profile/sexualhealth , as well as that of surrounding areas and adapt their strategy for HIV testing using the national guidelines.Commissioners can use these data to plan and ensure access to comprehensive and specialist local HIV care and treatment for HIV diagnosed individuals according to the http://www.medfash.org.uk/uploads/files/p17abl6hvc4p71ovpkr81ugsh60v.pdf and http://www.bhiva.org/monitoring-guidelines.aspx .Definition of numeratorThe number of people (aged 15 to 59 years) living with a diagnosed HIV infection and accessing HIV care at an NHS service in the UK and who are resident in England.Definition of denominatorResident population aged 15 to 59.The denominators for 2011 to 2023 are taken from the respective 2011 to 2023 Office for National Statistics (ONS) revised population estimates from the 2021 Census.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsData is presented by geographical area of residence. Where data on residence were unavailable, residence have been assigned to the local health area of care.Every effort is made to ensure accuracy and completeness of the data, including web-based reporting with integrated checks on data quality. The overall data quality is high as the dataset is used for commissioning purposes and for the national allocation of funding. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is as reported but rely on ‘record linkage’ to integrate data and ‘de-duplication’ to prevent double counting of the same individual. The data may not be representative in areas where residence information is not known for a significant proportion of people accessing HIV care.Data supplied for previous years are updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may therefore differ from previous publications.Values are benchmarked against set thresholds and categorised into the following groups: <2 (low), 2 to 5 (high) and≥5 (extremely high). These have been determined by developments in national testing guidelines.The data reported in 2020 and 2021 is impacted by the reconfiguration of sexual health services during the national response to COVID-19.

The number of new cases of HIV diagnosed in the UK fluctuated over the observed period. In 2023, there were ***** new HIV cases recorded in the UK, highest in the given period. Cases of AIDS in the UK were significantly lower, with *** cases in 2023. STIs in the UK Other common STIs in the UK are herpes, gonorrhea, and chlamydia. Especially for gonorrhea and chlamydia, an increase in cases was observed between 2012 and 2019, while in 2020 and 2021 figures fell dramatically due to the COVID-19 pandemic and resulting lockdowns and social distancing. HIV in Europe New cases of HIV in Europe amounted to roughly **** thousand in 2023, of which **** thousand were among males. Among male individuals, the most common mode of HIV transmission in Europe in 2023 was among men having homosexual intercourse.

Unlinked anonymous Serosurveys of HIV prevalence (diagnosed and undiagnosed infections) - Neonatal dried blood spots

BackgroundTo examine the effect of Sexual Health in Practice (SHIP) training for general practitioners (GPs) on HIV testing rates in Haringey, a deprived area of London, UK, with a population of over 250,000 and HIV prevalence of 0.7% (in 2014). SHIP is an educational intervention delivering peer-developed and peer-led face-to-face training to improve quality of sexual and reproductive health (SRH) care.MethodsWe carried out a quasi-experimental study of intervention effects across 52 GP practices (2008–2016). We used time variation in SHIP intervention exposure for effect estimation, controlling for practice and calendar month fixed effects in panel analysis. From 2008–2010, baseline data were collected, and in the subsequent six-year period, 78 GPs in Haringey (approximately 40% of all GPs) were SHIP trained. 46 Haringey practices (of 52) had at least one trained doctor. Outcome measures were monthly HIV tests and results by practice (obtained from the hospital laboratories).ResultsSHIP significantly increased HIV testing; for every GP trained, practice HIV testing rates increased by 16% (testing rate ratio (TRR) 1.16, 95% confidence interval (CI) 1.05–1.28, p value 0.004). This significant effect was demonstrated using an 8-year observation period, and was sustained over the post-intervention period. An average of 1.42% of HIV tests were positive.ConclusionSHIP training produces a significant and sustained increase in HIV testing for each GP trained. Compared with general population screening, HIV tests used in routine clinical care have a high probability of detecting a positive person. Unlike an RCT, this evaluation is a ‘real life’ measure of the effect that commissioners of SHIP could expect in comparable areas of the UK. The effectiveness of the SHIP training may be related to the programme components not included in interventions that did not demonstrate an effect, such as peer-led teaching, and use of approaches to communication and rapid risk assessment tailored to the setting.

The number of new cases of AIDS diagnosed in the UK generally decreased over the period observed to *** cases in 2023. This statistic displays the number of new cases of AIDS diagnosed in the United Kingdom from 2013 to 2023.

Measure the proportion of undiagnosed HIV prevalence in GUM clinics

BackgroundThere is interest in expanding ART to prevent HIV transmission, but in the group with the highest levels of ART use, men-who-have-sex-with-men (MSM), numbers of new infections diagnosed each year have not decreased as ARTcoverage has increased for reasons which remain unclear. MethodsWe analysed data on the HIV-epidemic in MSM in the UK from a range of sources using an individual-based simulation model. Model runs using parameter sets found to result in good model fit were used to infer changes in HIV-incidence and risk behaviour. ResultsHIV-incidence has increased (estimated mean incidence 0.30/100 person-years 1990–1997, 0.45/100 py 1998–2010), associated with a modest (26%) rise in condomless sex. We also explored counter-factual scenarios: had ART not been introduced, but the rise in condomless sex had still occurred, then incidence 2006–2010 was 68% higher; a policy of ART initiation in all diagnosed with HIV from 2001 resulted in 32% lower incidence; had levels of HIV testing been higher (68% tested/year instead of 25%) incidence was 25% lower; a combination of higher testing and ART at diagnosis resulted in 62% lower incidence; cessation of all condom use in 2000 resulted in a 424% increase in incidence. In 2010, we estimate that undiagnosed men, the majority in primary infection, accounted for 82% of new infections. ConclusionA rise in HIV-incidence has occurred in MSM in the UK despite an only modest increase in levels of condomless sex and high coverage of ART. ART has almost certainly exerted a limiting effect on incidence. Much higher rates of HIV testing combined with initiation of ART at diagnosis would be likely to lead to substantial reductions in HIV incidence. Increased condom use should be promoted to avoid the erosion of the benefits of ART and to prevent other serious sexually transmitted infections.

Background The study objectives were to measure disability prevalence and severity, and examine disability risk factors, among adults living with HIV in London, United Kingdom (UK). Methods Self-reported questionnaires were administered: World Health Organization Disability Assessment Schedule 2.0 (WHODAS), HIV Disability Questionnaire (HDQ), Equality Act disability definition (EADD), and demographic questionnaire. We calculated proportion (95% Confidence Interval; CI) of “severe” and “moderate” disability measured using EADD and WHODAS scores ≥2 respectively. We measured disability severity with HDQ domain severity scores. We used demographic questionnaire responses to assess risk factors of “severe” and “moderate” disability using logistic regression analysis, and HDQ severity domain scores using linear regression analysis. Results Of 201 participants, 176 (87.6%) identified as men, median age 47 years, and 194 (96.5%) virologically suppressed. Severe disability prevalence was 39.5% (n=79/201), 95% CI [32.5%, 46.4%]. Moderate disability prevalence was 70.5% (n=141/200), 95% CI [64.2%, 76.8%]. Uncertainty was the most severe HDQ disability domain. Late HIV diagnosis was a risk factor for severe disability [Odds Ratio (OR) 2.71; CI 1.25, 5.87]. Social determinants of health, economic inactivity [OR 2.79; CI 1.08, 7.21] and receiving benefits [OR 2.87; CI 1.05, 7.83], were risk factors for “severe” disability. Economic inactivity [OR 3.14; CI 1.00, 9.98] was a risk factor for “moderate” disability. Economic inactivity, receiving benefits, and having no fixed abode were risk factors (P≤0.05) across HDQ domains; physical, mental and emotional, difficulty with day-to-day activities, and challenges to social participation. Personal factors, identifying as a woman and being aged <50 years, were risk factors (P≤0.05) for HDQ domains; mental and emotional, uncertainty, and challenges with social participation. Conclusions People living with well-controlled HIV in London UK experienced multi-dimensional and episodic disability. Results help to better understand the prevalence, severity, and risk factors of disability experienced by adults living with HIV, identify areas to target interventions, and optimise health and functioning.

All new STI diagnoses among people accessing sexual health services* in England. Data represent STI diagnoses among people who are resident in England. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included). Data is expressed as a rate per 100,000 population.*Sexual health services providing STI related care (Levels 1, 2 or 3). Further details on the levels of sexual healthcare provision are provided in the Standards for the Management of STIs.

Rationale A summary figure of all new STI diagnoses.

Definition of numerator The number of new STI diagnoses among people accessing sexual health services in England who are also residents in England.STI data excluding chlamydia is sourced from the GUMCAD STI Surveillance System (Levels 2 and 3). GUMCAD data is reported by SHSs providing STI related care (Levels 2 or 3). Chlamydia data is sourced from GUMCAD (Level 3) and CTAD Chlamydia Surveillance System (Levels 1 and 2), UKHSA. CTAD data is reported by laboratories conducting testing for any service (Levels 1, 2 or 3) providing chlamydia testing.The Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of: chancroid, Lymphogranuloma venereum (LGV), donovanosis, chlamydia, gonorrhoea, first episode anogenital herpes, new HIV diagnosis, molluscum contagiosum, non-specific genital infection (NSGI), pelvic inflammatory disease (PID) and epididymitis: non-specific, scabies and pediculosis pubis, syphilis (primary, secondary and early latent), trichomoniasis, first episode genital warts were used.In 2015, the new STI diagnoses group was expanded to include new codes that were not previously reported via GUMCADv2. The new codes include: Mycoplasma genitalium (C16); Shigella: flexneri, sonnei and unspecified (SG1, SG2, SG3).The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.

Definition of denominator The denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .Caveats Every effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

The heterosexual risk group has become the largest HIV infected group in the United Kingdom during the last 10 years, but little is known of the network structure and dynamics of viral transmission in this group. The overwhelming majority of UK heterosexual infections are of non-B HIV subtypes, indicating viruses originating among immigrants from sub-Saharan Africa. The high rate of HIV evolution, combined with the availability of a very high density sample of viral sequences from routine clinical care has allowed the phylodynamics of the epidemic to be investigated for the first time. Sequences of the viral protease and partial reverse transcriptase coding regions from 11,071 patients infected with HIV of non-B subtypes were studied. Of these, 2774 were closely linked to at least one other sequence by nucleotide distance. Including the closest sequences from the global HIV database identified 296 individuals that were in UK-based groups of 3 or more individuals. There were a total of 8 UK-based clusters of 10 or more, comprising 143/2774 (5%) individuals, much lower than the figure of 25% obtained earlier for men who have sex with men (MSM). Sample dates were incorporated into relaxed clock phylogenetic analyses to estimate the dates of internal nodes. From the resulting time-resolved phylogenies, the internode lengths, used as estimates of maximum transmission intervals, had a median of 27 months overall, over twice as long as obtained for MSM (14 months), with only 2% of transmissions occurring in the first 6 months after infection. This phylodynamic analysis of non-B subtype HIV sequences representing over 40% of the estimated UK HIV-infected heterosexual population has revealed heterosexual HIV transmission in the UK is clustered, but on average in smaller groups and is transmitted with slower dynamics than among MSM. More effective intervention to restrict the epidemic may therefore be feasible, given effective diagnosis programmes.

Snapshot img

HIV Drugs Market Size 2024-2028

The hiv drugs market size is forecast to increase by USD 9.99 billion at a CAGR of 5.02% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. The increasing prevalence of HIV AIDS worldwide continues to drive market expansion. According to the World Health Organization, there were approximately 38 million people living with HIV in 2019. Moreover, expanding access to HIV treatment is another major growth factor. With advancements in HIV treatment, more individuals are able to access life-saving medications. However, drug resistance among individuals poses a significant challenge to the market. As HIV strains become resistant to current treatments, the development of new and effective drugs is crucial. This report provides a comprehensive analysis of these trends and challenges, offering insights into the future growth prospects of the market.

What will be the Size of the HIV Drugs Market During the Forecast Period?

Request Free SampleThe market encompasses a range of pharmaceutical products designed to manage and suppress the viral infection caused by Human Immunodeficiency Virus (HIV). This market has experienced significant growth due to the increasing prevalence of HIV and the ongoing development of new, more effective medications. Notable classes of HIV drugs include those containing CD4 modulators, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, and Epzicom. New product launches continue to drive market expansion, with companies investing in research and development to improve treatment outcomes and patient compliance. The healthcare products industry plays a crucial role In the import and export of HIV medications, ensuring access to these essential treatments for patients worldwide.HIV testing procedures remain a critical aspect of disease management and prevention efforts, further fueling demand for HIV medications withIn the market.

How is this HIV Drugs Industry segmented and which is the largest segment?

The hiv drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Distribution ChannelOfflineOnlineTherapyCombination HIV medicinesIntegrase inhibitorsNon-nucleoside reverse transcriptase inhibitorsOthersGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

Offline distribution channels, including pharmacies, drugstores, hospitals, and clinics, remain a significant segment In the market. Pharmacies and drugstores serve as crucial points of sale for HIV medications, particularly antiretroviral therapy (ART), which is essential for managing HIV/AIDS. The offline distribution segment caters to various patient populations, including those in regions with limited internet access or who prefer face-to-face interactions with healthcare professionals. Key HIV drugs, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca, are distributed offline through these channels.The offline distribution segment's growth is influenced by factors like the prevalence of HIV, testing procedures, and the availability of various HIV medications. Import and export regulations, as well as the increasing demand for healthcare products, further impact this market.

Get a glance at the HIV Drugs Industry report of share of various segments Request Free Sample

The Offline segment was valued at USD 25.82 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 49% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The North American the market has experienced substantial growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness about HIV/AIDS. With a significant patient population and established healthcare systems In the United States, Canada, and Mexico, North America is a leading market for HIV drugs. Key trends include the development of combination HIV medicines, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norv

The 2011 Uganda AIDS Indicator Survey (AIS) is a nationally representative, population-based, HIV serological survey. The survey was designed to obtain national and sub-national estimates of the prevalence of HIV and syphilis infection as well as information about other indicators of programme coverage, such as knowledge, attitudes, and sexual behaviour related to HIV/AIDS. Data collection took place from 8 February to the first few days of September 2011. The UAIS was implemented by the Ministry of Health. ICF International provided financial and technical assistance for the survey through a contract with USAID/Uganda. Financial and technical assistance was also provided by the U.S. Centers for Disease Control and Prevention (CDC). Financial support was provided by the Government of Uganda, the U.S. Agency for International Development (USAID), the President’s Emergency Fund for AIDS Relief (PEPFAR), the World Health Organisation (WHO), the UK Department for International Development (DFID), and the Danish International Development Agency (DANIDA) through the Partnership Fund. The Uganda Bureau of Statistics also partnered in the implementation of the survey. Central testing was conducted at the Uganda Virus Research Institute, with CDC conducting CD4 counts, polymerase chain reaction (PCR) testing for children, and quality control tests. The survey provided information on knowledge, attitudes, and behaviour regarding HIV/AIDS and indicators of coverage and access to other programmes, for example, HIV testing, access to antiretroviral therapy, services for treating sexually transmitted infections, and coverage of interventions to prevent motherto-child transmission of HIV. The survey also collected information on the prevalence of HIV and syphilis and their social and demographic variations in the country. The overall goal of the survey was to provide programme managers and policymakers involved in HIV/AIDS programmes with strategic information to effectively plan, implement, and evaluate HIV/AIDS interventions. The information obtained from the survey will help programme implementers to monitor and evaluate existing programmes and design new strategies for combating the HIV/AIDS epidemic in Uganda. The survey data will in addition be used to make population projections and to calculate indicators developed by the UN General Assembly Special Session (UNGASS), USAID, PEPFAR, the UNAIDS Programme, WHO, the Uganda Health Sector Strategic and Investment Plan, and the Uganda AIDS Commission. The specific objectives of the 2011 UAIS were to provide information on: • Prevalence and distribution of HIV and syphilis • Indicators of knowledge, attitudes, and behaviour related to HIV/AIDS and other sexually transmitted infections • HIV/AIDS programme coverage indicators • Levels of CD4 T-lymphocyte counts among HIV-positive adults to quantify HIV treatment needs and to calibrate model-based estimates • HIV prevalence that can be used to calibrate and improve the sentinel surveillance system • Risk factors for HIV and syphilis infections in Uganda.

Background: The disease burden of hepatitis C virus (HCV) infection in HIV-positive and HIV-negative men who have sex with men (MSM) is changing. We aim to provide an updated comprehensive estimate of HCV prevalence and incidence among the HIV-positive and HIV-negative MSM population at the country, regional, and global levels and their changing trends over time.Methods: PubMed, Embase, PsycINFO, CINAHL, and conference databases were searched and eligible records on the prevalence and incidence of HCV antibodies were selected and pooled via a random-effects model. Meta-regression was performed to demonstrate the association between the pooled rates and study year.Results: A total of 230 articles reporting 245 records from 51 countries with 445,883 participants and 704,249 follow-up person-years were included. The pooled prevalence of HCV in MSM was 5.9% (95% CI: 5.1–6.8), with substantial differences between countries and regions. Low- and lower-middle-income countries (12.3 and 7.0%) manifested a larger disease burden than high- and upper-middle-income countries (5.8 and 3.8%). HCV prevalence in HIV-positive MSM was substantially higher than in HIV-negative MSM (8.1 vs. 2.8%, p < 0.001). The pooled incidence of HCV was 8.6 (95% CI: 7.2–10.0) per 1,000 person-years, with an increasing trend over time, according to meta-regression (p < 0.05).Conclusion: Global HCV prevalence in MSM varies by region and HIV status. Behavior counseling and regular HCV monitoring are needed in HIV-positive subgroups and high-risk regions. Given the upward trend of HCV incidence and sexual risk behaviors, there is also a continued need to reinforce risk-reduction intervention.Systematic Review Registration: PROSPERO, identifier CRD42020211028; https://www.crd.york.ac.uk/prospero/.

IntroductionPeople living with HIV (PLWH) now have near-normal life-expectancy, but still experience stigma, and HIV status is treated as sensitive health information. When UK healthcare patient data is curated into anonymised datasets for research, HIV diagnostic codes are stripped out. As PLWH age, we must research how HIV affects conditions of ageing, but cannot do so in current NHS research datasets. We aimed to elicit views on HIV status being shared in NHS datasets, and identify appropriate safeguards.MethodsWe conducted three focus groups with a convenience sample of PLWH recruited through HIV charities, presenting information on data governance, data-sharing, patient privacy, law, and research areas envisaged for HIV and ageing. Each focus group involved two presentations, a question session, and facilitated breakout discussion groups. Discussions were audio-recorded, transcribed and analysed thematically.Results37 PLWH (age range 23-58y) took part. The overarching theme was around trust, both the loss of trust experienced by participants due to previous negative or discriminatory experiences, and the need to slowly build trust in data-sharing initiatives. Further themes showed that participants were supportive of data being used for research and health care improvements, but needed a guarantee that their privacy would be protected. A loss of trust in systems and organisations using the data, suspicion of data users’ agendas, and worry about increased discrimination and stigmatisation made them cautious about data sharing. To rebuild trust participants wanted to see transparent security protocols, accountability for following these, and communication about data flows and uses, as well as awareness training about HIV, and clear involvement of PLWH as full stakeholders on project teams and decision-making panels.ConclusionsPLWH were cautiously in favour of their data being shared for research into HIV, where this could be undertaken with high levels of security, and the close involvement of PLWH to set research agendas and avoid increased stigma.

Snapshot img

Point Of Care (Poc) Hiv Testing Market Size 2024-2028

The point of care (poc) hiv testing market size is forecast to increase by USD 329.8 million at a CAGR of 3.2% between 2023 and 2028.

The market is witnessing significant growth due to several key factors. The increasing prevalence of HIV/AIDS worldwide continues to drive market demand, as early and accurate diagnosis is crucial for effective treatment and management of the disease. Additionally, rising awareness programs for HIV testing, particularly in developing and underdeveloped nations, are expanding access to testing services and boosting market growth. Limited healthcare infrastructure In these regions necessitates the use of PoC HIV testing devices, which offer rapid results and ease of use. These trends are expected to continue shaping the market dynamics In the coming years.

What will be the Size of the Point Of Care (Poc) Hiv Testing Market During the Forecast Period?

Request Free Sample

The market encompasses diagnostic devices and kits designed for rapid HIV testing at patient locations outside of centralized laboratories. With the global HIV/AIDS prevalence rate continuing to rise, there is a growing demand for convenient and quick HIV testing solutions. POC HIV testing is particularly relevant to scenarios involving blood transfusions and donations, as well as in healthcare institutions and home healthcare settings. These tests provide immediate results, enabling timely treatment decisions and improved patient outcomes. The market is also influenced by the increasing prevalence of chronic diseases such as HIV, tuberculosis, and influenza, which necessitate early detection and personalized medicine.
Additionally, demographic trends, including an aging population and increased patient autonomy, are driving the growth of the POC HIV testing market. Despite the advantages, challenges such as turnaround time and cost remain, necessitating ongoing innovation and competition withIn the market.

How is this Point Of Care (Poc) Hiv Testing Industry segmented and which is the largest segment?

The point of care (poc) hiv testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  POC HIV testing equipment
  POC HIV testing reagents


End-user

  Diagnostic labs
  Hospitals and clinics
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France


  Asia

    China


  Rest of World (ROW)

By Product Insights

The poc hiv testing equipment segment is estimated to witness significant growth during the forecast period.

POC HIV testing equipment refers to devices and tools used for HIV testing at or near the patient's care location. This includes rapid HIV test kits, POC HIV viral load testing systems, and POC CD4 count devices. POC testing plays a crucial role in expanding HIV testing access, improving early diagnosis, and increasing linkage to care, particularly in underdeveloped nations and community-based programs. Early diagnosis and swift treatment initiation are essential strategies to combat HIV spread. POC HIV testing equipment advances diagnostics and clinical services, enabling healthcare institutions to provide ART supplies and minimize turnaround time. UNAIDS reports that HIV-related mortality and new infections can be reduced through widespread testing, pre- and post-test counselling, and timely interventions.

Key dynamics driving the POC HIV testing market include chronic diseases, lifestyle-borne diseases, real-time diagnosis, miniaturization of devices, and advanced technologies like biosensors and nanotechnology. Cost-effective, rapid testing is essential for patient management of target diseases, including blood-related disorders and infectious diseases like influenza, HIV, and tuberculosis.

Get a glance at the Point Of Care (Poc) Hiv Testing Industry report of share of various segments Request Free Sample

The POC HIV testing equipment segment was valued at USD 1575.00 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America has experienced notable growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness regarding HIV/AIDS. The market caters to the US, Canada, and Mexico, with the region's well-developed healthcare system and thriving industry fueling demand for HIV treatment solutions

All diagnoses of first episode genital herpes among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGenital herpes is the most common ulcerative sexually transmitted infection seen in England. Infections are frequently due to herpes simplex virus (HSV) type 2, although HSV-1 infection is also seen. Recurrent infections are common with patients returning for treatment.Definition of numeratorThe number of diagnoses of genital herpes (first episode) among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of genital herpes (first episode) were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

BackgroundIn the UK, approximately 4,200 men who have sex with men (MSM) are living with HIV but remain undiagnosed. Maximising the number of high-risk people testing for HIV is key to ensuring prompt treatment and preventing onward infection. This study assessed how different HIV test characteristics affect the choice of testing option, including remote testing (HIV self-testing or HIV self-sampling), in the UK, a country with universal access to healthcare.Methods and findingsBetween 3 April and 11 May 2017, a cross-sectional online-questionnaire-based discrete choice experiment (DCE) was conducted in which respondents who expressed an interest in online material used by MSM were asked to imagine that they were at risk of HIV infection and to choose between different hypothetical HIV testing options, including the option not to test. A variety of different testing options with different defining characteristics were described so that the independent preference for each characteristic could be valued. The characteristics included where each test is taken, the sampling method, how the test is obtained, whether infections other than HIV are tested for, test accuracy, the cost of the test, the infection window period, and how long it takes to receive the test result. Participants were recruited and completed the instrument online, in order to include those not currently engaged with healthcare services. The main analysis was conducted using a latent class model (LCM), with results displayed as odds ratios (ORs) and probabilities. The ORs indicate the strength of preference for one characteristic relative to another (base) characteristic. In total, 620 respondents answered the DCE questions. Most respondents reported that they were white (93%) and were either gay or bisexual (99%). The LCM showed that there were 2 classes within the respondent sample that appeared to have different preferences for the testing options. The first group, which was likely to contain 86% of respondents, had a strong preference for face-to-face tests by healthcare professionals (HCPs) compared to remote testing (OR 6.4; 95% CI 5.6, 7.4) and viewed not testing as less preferable than remote testing (OR 0.10; 95% CI 0.09, 0.11). In the second group, which was likely to include 14% of participants, not testing was viewed as less desirable than remote testing (OR 0.56; 95% CI 0.53, 0.59) as were tests by HCPs compared to remote testing (OR 0.23; 95% CI 0.15, 0.36). In both classes, free remote tests instead of each test costing £30 was the test characteristic with the largest impact on the choice of testing option. Participants in the second group were more likely to have never previously tested and to be non-white than participants in the first group. The main study limitations were that the sample was recruited solely via social media, the study advert was viewed only by people expressing an interest in online material used by MSM, and the choices in the experiment were hypothetical rather than observed in the real world.ConclusionsOur results suggest that preferences in the context we examined are broadly dichotomous. One group, containing the majority of MSM, appears comfortable testing for HIV but prefers face-to-face testing by HCPs rather than remote testing. The other group is much smaller, but contains MSM who are more likely to be at high infection risk. For these people, the availability of remote testing has the potential to significantly increase net testing rates, particularly if provided for free.

All gonorrhoea diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGonorrhoea causes avoidable sexual and reproductive ill-health. Gonorrhoea is used as a marker for rates of unsafe sexual activity. This is because the majority of cases are diagnosed in sexual health clinics, and consequently the number of cases may be a measure of access to sexually transmitted infection (STI) treatment. Infections with gonorrhoea are also more likely than chlamydia to result in symptoms.Definition of numeratorThe number of gonorrhoea diagnoses among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of gonorrhoea were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.